Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOB3CI)

• Drug Name: ALXN1720 Drug Info
• Synonyms: gefurulimab

Indication

Disease Entry	ICD 11	Status	REF
Generalized myasthenia gravis	8C60	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DMOB3CI

Molecule-Related Drug Atlas

Drug(s) Targeting Complement C5 (CO5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ravulizumab	DMSWNJF	Paroxysmal nocturnal haemoglobinuria	3A21.0	Approved	[3]
Zilucoplan	DM9Z4N5	Generalized myasthenia gravis	8C60	Approved	[4]
Pozelimab	DMTE8DC	Large B Cell Lymphoma		Approved	[5]
Avacincaptad pegol	DM1Z3Z2	Geographic atrophy	9B75	Approved	[6]
SKY59	DMWOF1E	Haemolytic uraemic syndrome	3A21.2	Phase 3	[7]
SB12	DMME6GJ	Paroxysmal nocturnal haemoglobinuria	3A21.0	Phase 3	[8]
Zimura	DM09TVB	Macular degeneration	9B78.3	Phase 3	[9]
ABP959	DMDXE4I	Paroxysmal nocturnal haemoglobinuria	3A21.0	Phase 3	[10]
Coversin	DMMEAOL	Paroxysmal nocturnal haemoglobinuria	3A21.0	Phase 3	[11]
Nomacopan	DML6E6G	Bullous pemphigoid	EB41.0	Phase 3	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Complement C5 (CO5)	TTKANGO	CO5_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT05556096) A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis. U.S.National Institutes of Health.
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [3] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.
• [6] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217225
• [7] The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920.
• [8] Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019 Sep;18(9):707-729.
• [9] C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586.
• [10] A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris ?) in healthy male subjects. Eur J Haematol. 2020 Jul;105(1):66-74.
• [11] Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv. 2017 Jul 3;1(16):1254-1258.
• [12] Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial. JAMA Dermatol. 2022 Jun 1;158(6):641-649.